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CASE PRESENTATION
A 60 year-old Caucasian female who developed chronic
renal failure from focal segmental glomerulosclerosis
(FSGS) received a living-related renal allograft from her 28-
year-old son. The patient presented initially at age 48 with
signs of nephrotic syndrome (peripheral edema, hypoal-
buminemia, and hypercholesterolemia) and a serum
creatinine of 1.5 mg/dl (132mmol/l) (normal range
0.6–1.2 mg/dl (52.8–105.6mmol/l)). She was treated with
prednisone for six months, followed by cyclosporine A,
with only partial remission of proteinuria. Renal function
slowly declined over the ensuing decade. At the time of
initial presentation, serologic test results were negative or
within normal limits for antinuclear antibody, C3 and C4
complement levels, hepatitis B surface antigen, hepatitis C
antibody, and serum and urine protein electrophoreses.
Her past medical history was significant for hypertension
for 25 years, and hypothyroidism. She had no history of
childhood urinary tract infections or urinary reflux and she
denied regular intake of over-the-counter medications.
The patient’s post-operative course was unremarkable
and she was discharged seven days post-transplantation
with a serum creatinine of 1 mg/dl. Immunosuppressive
medications included FK506, mycophenolate mofetil, and
prednisone.
Four weeks post-transplant, the patient noted wor-
sening lower extremity edema. A 24-hour urine collection
contained 4.5 g protein (normal range 0–150 mg/day).
Serum albumin was 3.6 g/dl (36 g/l) (normal range
3.5–5.0 g/dl (30–50 g/l)) and serum creatinine was 1.0 mg/
dl (88.4mmol). FK506 levels were within therapeutic range.
A renal ultrasound showed no signs of urinary tract
outflow obstruction and normal venous and arterial blood
flow. A renal biopsy was performed.
RENAL BIOPSY FINDINGS
Twenty-four glomeruli were sampled for light microscopy,
none of which showed segmental or global glomerulosclero-
sis (Figure 1). Peripheral capillary lumina were fully patent
and glomerular basement membranes were uniformly
normal in thickness, contour and texture. There was a
minimal patchy interstitial mononuclear inflammatory cell
infiltrate, involving o5% of the cortical area, with rare foci
of mild tubulitis (o5 mononuclear inflammatory cells/
tubular cross-section). There was no significant tubular
atrophy or interstitial fibrosis. Features of isometric tubular
vacuolization or viral inclusions were not identified. Arterial
vessels were unremarkable. Immunofluorescence microscopy
showed no staining of peritubular capillaries for C4d and no
glomerular staining for IgG, IgM, IgA, C3, C1, fibrinogen,
albumin, kappa, or lambda. Electron microscopic examina-
tion of two glomeruli revealed diffuse (100%) podocyte foot
process effacement and no other significant ultrastructural
abnormalities (Figure 2).
PATHOLOGIC DIAGNOSIS
There was no evidence of immune complex mediated
glomerular disease, transplant glomerulopathy, or chronic
allograft nephropathy. The minimal interstitial inflammation
was insufficient for diagnosis of acute cellular rejection by the
Banff schema. The findings of diffuse podocyte foot process
effacement correlated with the clinical history of nephrotic
range proteinuria and suggested a primary podocyte disease,
either de novo minimal change disease or recurrent FSGS.
Given the history of FSGS in the native kidney, a diagnosis of
recurrent FSGS was favored, despite the absence of segmental
sclerosis lesions.
FOLLOW-UP
Following the allograft biopsy, the patient underwent daily
plasmapheresis for two weeks, followed by alternate day
plasmapheresis for a further two weeks. Her other immuno-
suppressive medications were unchanged. Following plasma-
pheresis, proteinuria declined to o1 g/day; serum creatinine
remained stable at 1 mg/dl (88.4 mmol). Seventeen months
later, the nephrotic syndrome recurred and a repeat
renal biopsy showed FSGS with segmental sclerosis
lesions in two of seven glomeruli (Figure 3). The segmental
lesions consisted of tuft adhesion to Bowman’s capsule,
accumulations of hyaline, and endocapillary mononuclear
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inflammatory cell accumulation. Glomerular basement
membrane duplication was not seen. There was no evidence
of cellular or humoral rejection, and no significant tubulo-
interstitial scarring or vessel disease. Electron microscopy was
not performed. Over the ensuing two weeks, proteinuria
returned too1 g/day, despite no additional therapy. At three
years post-transplantation, graft function remains stable,
albeit with continued mild proteinuria.
DISCUSSION
Proteinuria following renal transplantation may result from
diverse pathogenetic mechanisms, with different implications
for graft survival. Proteinuria in the first several weeks
post-transplantation is most commonly related to defective
tubular reabsorption due to acute tubular injury or acute
cellular rejection; this form of proteinuria is usually mild
(o1 g/day) and reversible, and is not an independent risk
factor for poor graft survival.1,2 Persistent post-transplanta-
tion proteinuria, however, particularly when in the nephrotic
range (43 g/day), is associated with decreased long-term
graft survival.2 Nephrotic range proteinuria occurs in up
to 13% of renal allograft recipients, and may develop at
any time, from immediately post-operatively to many years
post-transplantation.2,3
The major pathologic findings in post-transplant nephro-
tic syndrome are chronic allograft nephropathy (with or
without features of transplant glomerulopathy or secondary
focal segmental glomerulosclerosis), recurrent glomerular
disease, and de novo glomerular disease.3,4 Amongst recurrent
glomerular diseases causing post-transplant nephrotic syn-
drome, idiopathic FSGS is the most important in terms of
frequency and impact on graft survival.5 FSGS recurs in up to
30% of cases and graft loss ensues in 50% of affected
individuals. Recurrence is more common in children o15
years of age, in whom it develops more rapidly than in adults
(median 2 weeks6 versus mean 7.5 months7). Recurrence is
also more common in children whose native kidney biopsy
showed mesangial hypercellularity,8 in patients who had an
accelerated clinical course in the native kidney (progression
to end-stage renal disease within 3 years of onset of nephrotic
syndrome), in re-transplanted patients who lost a previous
graft to recurrent FSGS,5 and in Caucasians.5 Recurrence may
also be more frequent in patients with collapsing FSGS,
reflecting the rapidly progressive clinical course in many of
these cases.
Clinical and pathologic studies have provided important
insights into the pathogenesis of recurrent FSGS and some of
this information may also be relevant to idiopathic FSGS in
Figure 1 | Light microscopy shows a normal-appearing glomer-
ulus. Peripheral capillary are patent and glomerular basement
membranes appear normal in thickness, contour, and texture.
(Periodic acid Schiff reaction, original magnification  400).
Figure 2 | Electron microscopy discloses diffuse podocyte foot
process effacement, consistent with recurrent idiopathic focal
segmental glomerulosclerosis. (Electron micrograph, original
magnification  2000).
Figure 3 | Light microscopy shows of a subsequent allograft
biopsy shows a glomerulus with a segmental sclerosis and
hyalinosis lesion. (Periodic acid Schiff reaction, original
magnification  400).
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the native kidney. The early onset of nephrotic syndrome,
sometimes within minutes or hours of transplantation, is
associated with a circulating glomerular permeability factor
in the sera of some patients with recurrent FSGS.9 This 50 kD
anionic factor, whose precise nature remains elusive, causes
increased albumin permeability in isolated rat glomeruli and
increased proteinuria when injected in rats. Plasmapheresis
or immunoadsorption with protein A is associated with
reduced permeability factor activity and remission of
proteinuria in some patients with recurrent FSGS, while
relapse of nephrotic syndrome is accompanied by increased
permeability factor activity, strongly suggesting a pathoge-
netic role. A bioassay for permeability factor activity is
available; however, although higher levels of factor activity
are associated with increased likelihood of developing
recurrent FSGS, the predictive value of an abnormal test
result in individual patients is limited.9 Moreover, plasma-
pheresis has shown limited efficacy in the treatment of native
kidney FSGS, despite reduction in permeability factor
activity, implying that other factors besides glomerular
permeability factor contribute to proteinuria in native
FSGS.10,11 Recently, an increased incidence of recurrent FSGS
in children has been linked to the introduction of induction
therapy with daclizumab, an anti-IL-2 receptor antibody,
consistent with a pathogenic role for dysregulated
T-lymphocyte function in this condition.12
Serial biopsies in individual patients with recurrent FSGS
show evolution of the pathologic lesions over time.
Importantly, recurrence of proteinuria and nephrotic syn-
drome may precede the development of FSGS lesions by
weeks or months13–15 and initial biopsies may show normal-
appearing glomeruli with ultrastructural findings of diffuse
foot process effacement, as seen in the present case. Similar
pathologic findings may also be seen in de novo minimal
change disease,16,17 a diagnosis that should be precluded in
patients who have a native kidney diagnosis of FSGS. The
glomeruli of children with recurrent FSGS may show
enlargement,18 similar to findings in children with idiopathic
FSGS in the native kidney,19 suggesting a role for growth
factors in the early development of childhood FSGS. When
segmental lesions are seen in early biopsies of recurrent FSGS,
these often have a ‘cellular’ quality, with features of endo-
capillary proliferation, foam cell accumulation, hypertrophy
and hyperplasia of overlying podocytes, with or without
features of capillary collapse.9–11 Later biopsies and trans-
plant nephrectomies demonstrate more classic sclerosing
lesions, characterized by accumulations of matrix and
hyaline. These findings suggest that cellular lesions represent
an early stage in the morphologic evolution of FSGS.14
Immunohistochemical studies in recurrent FSGS have shown
that podocytes display phenotypic ‘trans-differentiation’, with
acquisition of macrophage and cell-cycle proliferation
markers, and aberrant expression of integrins and cyto-
keratins.15,20 Taken together, these findings support the
hypothesis that podocyte dysregulation is a central event
in the pathogenesis of primary FSGS, and provide evidence
that cellular FSGS lesions may represent an early stage of
disease.
Treatment of recurrent FSGS is challenging as most
patients are already receiving maintenance steroids and a
calcineurin inhibitor, and addition of a cytotoxic agent in this
immunocompromised population may be hazardous. As
mentioned, plasmapheresis or immunoadsorption with
protein A have shown benefit in some, but not all patients
with recurrent FSGS, and this benefit may relate to the
removal of a pathogenic circulating permeability factor.9
Plasmapheresis, especially when combined with increased
immunosuppression, appears to be particularly effective in
children with recurrent FSGS, with complete remission rates
of 75–100% described (reviewed in 21). Lower response rates
(46–67% with complete or partial remission) have been
reported in adults.21 Whether this reflects more aggressive
disease that is more refractory to treatment in adults is
uncertain. Other factors that may limit responsiveness
include delayed onset of FSGS, and delayed diagnosis and
initiation of plasmapheresis. In most studies, response to
plasmapheresis was associated with early initiation of therapy
and with early recurrence of FSGS post-transplantation
(i.e. within 3 months). Other therapies that have shown
benefit in some patients with recurrent FSGS include high
dose cyclosporine, ACE inhibition,7,12 and mycophenolate
mofetil,12 reflecting the efficacy of these agents in ameliorat-
ing proteinuria in native kidney diseases. Novel therapies that
may have a future role in managing recurrent FSGS include
bone marrow stem cell transplantation,22 pharmacologic
inhibition of the glomerular permeability factor,23 and
antibodies that inhibit CD80, a co-stimulatory molecule that
is upregulated by podocytes in nephrotic diseases.24
In summary, this case demonstrates many of the salient
clinical and pathologic characteristics of recurrent FSGS,
including: early onset of nephrotic syndrome post-transplan-
tation; initial biopsy findings of normal appearing glomeruli
with diffuse foot process effacement; appearance of segmental
sclerosis lesions in a subsequent biopsy; and response to
plasmapheresis. Heightened clinical awareness of this diagno-
sis is important, as characteristic FSGS lesions may be absent
in the early stage when plasmapheresis is potentially most
beneficial. Finally, this case illustrates the important role
of renal biopsy examination, including electron microscopy,
in the evaluation of the patient with post-transplantation
nephrotic syndrome.
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